Stifel lowered the firm’s price target on HLS Therapeutics (HLTRF) to C$4.45 from C$4.75 and keeps a Hold rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HLTRF:
- HLS Therapeutics Lifts Profitability, Cuts Debt as It Expands Cardiovascular Portfolio
- Is HLS a Buy, Before Earnings?
- HLS Therapeutics launches NILEMDO in Canada to tackle unmet cholesterol treatment needs
- HLS Therapeutics launches NILEMDO in Canada to target unmet LDL-cholesterol needs
- HLS Therapeutics Sets March 12 Date for Fiscal 2025 Results and Investor Call